Stocks in play: HLS Therapeutics Inc.
Announces that it has entered into a Product Listing Agreement with the province of Alberta, for the listing and public reimbursement of Vascepa (icosapent ethyl). The PLA with Alberta Health is effective August 1. HLS Therapeutics Inc. shares T.HLS are trading unchanged at $3.35.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.